KR20210061350A - 길항성 항-종양 괴사 인자 수용체 슈퍼패밀리 폴리펩티드 - Google Patents

길항성 항-종양 괴사 인자 수용체 슈퍼패밀리 폴리펩티드 Download PDF

Info

Publication number
KR20210061350A
KR20210061350A KR1020217008246A KR20217008246A KR20210061350A KR 20210061350 A KR20210061350 A KR 20210061350A KR 1020217008246 A KR1020217008246 A KR 1020217008246A KR 20217008246 A KR20217008246 A KR 20217008246A KR 20210061350 A KR20210061350 A KR 20210061350A
Authority
KR
South Korea
Prior art keywords
amino acid
antigen
acid sequence
antibody
binding fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020217008246A
Other languages
English (en)
Korean (ko)
Inventor
데니스 엘. 파우스트맨
Original Assignee
더 제너럴 하스피탈 코포레이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 더 제너럴 하스피탈 코포레이션 filed Critical 더 제너럴 하스피탈 코포레이션
Priority to KR1020257040897A priority Critical patent/KR20260004528A/ko
Publication of KR20210061350A publication Critical patent/KR20210061350A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
KR1020217008246A 2018-08-20 2019-08-20 길항성 항-종양 괴사 인자 수용체 슈퍼패밀리 폴리펩티드 Ceased KR20210061350A (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020257040897A KR20260004528A (ko) 2018-08-20 2019-08-20 길항성 항-종양 괴사 인자 수용체 수퍼패밀리 폴리펩티드

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862765284P 2018-08-20 2018-08-20
US62/765,284 2018-08-20
PCT/US2019/047330 WO2020041361A1 (en) 2018-08-20 2019-08-20 Antagonistic anti-tumor necrosis factor receptor superfamily polypeptides

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020257040897A Division KR20260004528A (ko) 2018-08-20 2019-08-20 길항성 항-종양 괴사 인자 수용체 수퍼패밀리 폴리펩티드

Publications (1)

Publication Number Publication Date
KR20210061350A true KR20210061350A (ko) 2021-05-27

Family

ID=69591189

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020217008246A Ceased KR20210061350A (ko) 2018-08-20 2019-08-20 길항성 항-종양 괴사 인자 수용체 슈퍼패밀리 폴리펩티드
KR1020257040897A Pending KR20260004528A (ko) 2018-08-20 2019-08-20 길항성 항-종양 괴사 인자 수용체 수퍼패밀리 폴리펩티드

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020257040897A Pending KR20260004528A (ko) 2018-08-20 2019-08-20 길항성 항-종양 괴사 인자 수용체 수퍼패밀리 폴리펩티드

Country Status (7)

Country Link
US (2) US20210340268A1 (enExample)
EP (1) EP3840782A4 (enExample)
JP (2) JP7713880B2 (enExample)
KR (2) KR20210061350A (enExample)
CN (1) CN112955179A (enExample)
CA (1) CA3109954A1 (enExample)
WO (1) WO2020041361A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3936137A1 (en) * 2013-02-07 2022-01-12 The General Hospital Corporation Methods for expansion or depletion of t-regulatory cells
US11859002B2 (en) 2016-05-13 2024-01-02 The General Hospital Corporation Antagonistic anti-tumor necrosis factor receptor 2 antibodies

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115043943A (zh) 2015-05-15 2022-09-13 综合医院公司 拮抗性抗肿瘤坏死因子受体超家族抗体
KR102669985B1 (ko) 2015-06-30 2024-05-29 샌포드 번햄 프레비즈 메디컬 디스커버리 인스티튜트 Btla 융합 단백질 작용제 및 이의 용도
US20190135929A1 (en) 2015-08-28 2019-05-09 The General Hospital Corporation Agonistic anti-tumor necrosis factor receptor 2 antibodies
CN112955179A (zh) * 2018-08-20 2021-06-11 综合医院公司 拮抗性抗肿瘤坏死因子受体超家族多肽
CN113302205B (zh) 2018-11-15 2024-12-06 综合医院公司 激动性肿瘤坏死因子受体超家族多肽
EP4149627A4 (en) * 2020-05-14 2024-05-29 The General Hospital Corporation POLYPEPTIDE AGONISTS OF THE TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY
TWI878554B (zh) 2020-06-12 2025-04-01 大陸商南京維立志博生物科技股份有限公司 結合ｔｎｆｒ２的抗體及其用途
CN112159818B (zh) * 2020-08-20 2023-02-21 山东兴瑞生物科技有限公司 用于治疗hcc的核酸、其制备方法、具有该核酸的car-t细胞及细胞的制备方法
US20240101693A1 (en) * 2021-01-21 2024-03-28 The General Hospital Corporation Antagonistic anti-tumor necrosis factor receptor superfamily antibodies
CN117858893A (zh) * 2021-06-30 2024-04-09 盛禾(中国)生物制药有限公司 一种抗tnfr2单域抗体及其制备方法和应用
CN116334768A (zh) * 2022-07-14 2023-06-27 上海肽盛医药有限公司 一种结构多样的多肽库及其构建方法和应用
WO2024219994A1 (ru) * 2023-04-16 2024-10-24 федеральное государственное бюджетное учреждение "Национальный исследовательский центр эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи" Министерства здравоохранения Российской Федерации Экспрессионный вектор на основе аденовируса человека 19 серотипа и способ его применения
CN116650660B (zh) * 2023-07-27 2023-11-03 上海偌妥生物科技有限公司 制备抗体偶联小分子药物的方法及其应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5677425A (en) * 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
CN1771055A (zh) * 2002-09-05 2006-05-10 免疫医疗公司 通过施用cd2拮抗剂预防或治疗t细胞恶性肿瘤的方法
US7592429B2 (en) * 2005-05-03 2009-09-22 Ucb Sa Sclerostin-binding antibody
JP5898082B2 (ja) * 2009-10-07 2016-04-06 マクロジェニクス，インコーポレーテッド フコシル化程度の変更により改良されたエフェクター機能を示すＦｃ領域含有ポリペプチドおよびその使用法
AU2015237864B2 (en) * 2014-03-24 2020-12-03 Cancer Research Technology Limited Modified antibodies containing modified IgG2 domains which elicit agonist or antagonistic properties and use thereof
WO2016094309A1 (en) * 2014-12-10 2016-06-16 Myosotis Inhibition of tnf signaling in cancer immunotherapy
CA3004830A1 (en) * 2015-11-11 2017-05-18 Opi Vi- Ip Holdco Llc Composition and methods for anti-tnfr2 antibodies
US11859002B2 (en) * 2016-05-13 2024-01-02 The General Hospital Corporation Antagonistic anti-tumor necrosis factor receptor 2 antibodies
BR112019001206A2 (pt) * 2016-07-20 2019-06-25 Aerpio Therapeutics Inc anticorpos monoclonais humanizados que visam ve-ptp (hptp-ss)
WO2018031400A1 (en) * 2016-08-12 2018-02-15 Janssen Biotech, Inc. Fc engineered anti-tnfr superfamily member antibodies having enhanced agonistic activity and methods of using them
SG10201912565QA (en) * 2016-09-29 2020-02-27 Amgen Inc Low-viscosity antigen binding proteins and methods of making them
WO2018092907A1 (ja) * 2016-11-21 2018-05-24 国立研究開発法人医薬基盤・健康・栄養研究所 エピトープ均質化抗体パネル、ならびにその作製方法および利用
US20200347143A1 (en) * 2016-12-19 2020-11-05 Glenmark Pharmaceuticals S.A. Novel tnfr agonists and uses thereof
CN112955179A (zh) * 2018-08-20 2021-06-11 综合医院公司 拮抗性抗肿瘤坏死因子受体超家族多肽

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3936137A1 (en) * 2013-02-07 2022-01-12 The General Hospital Corporation Methods for expansion or depletion of t-regulatory cells
US11844814B2 (en) 2013-02-07 2023-12-19 The General Hospital Corporation Methods for expansion or depletion of T-regulatory cells
US11859002B2 (en) 2016-05-13 2024-01-02 The General Hospital Corporation Antagonistic anti-tumor necrosis factor receptor 2 antibodies

Also Published As

Publication number Publication date
WO2020041361A1 (en) 2020-02-27
US20230295326A1 (en) 2023-09-21
EP3840782A1 (en) 2021-06-30
US20210340268A1 (en) 2021-11-04
CA3109954A1 (en) 2020-02-27
CN112955179A (zh) 2021-06-11
JP2021534757A (ja) 2021-12-16
EP3840782A4 (en) 2022-06-08
AU2019324134A1 (en) 2021-04-15
JP2025118591A (ja) 2025-08-13
KR20260004528A (ko) 2026-01-08
JP7713880B2 (ja) 2025-07-28

Similar Documents

Publication Publication Date Title
US20250066494A1 (en) Antagonistic anti-tumor necrosis factor receptor superfamily polypeptides
US20240270860A1 (en) Antagonistic anti-tumor necrosis factor receptor superfamily antibodies
US20230295326A1 (en) Antagonistic anti-tumor necrosis factor receptor superfamily polypeptides
US20250051469A1 (en) Antagonistic anti-tumor necrosis factor receptor superfamily antibodies
US20220348645A1 (en) Conformation-specific antibodies that bind nuclear factor kappa-light-chain-enhancer of activated b cells
US20240101693A1 (en) Antagonistic anti-tumor necrosis factor receptor superfamily antibodies
AU2019324134B2 (en) Antagonistic anti-tumor necrosis factor receptor superfamily polypeptides
WO2025122817A1 (en) Antagonistic cd40 antibodies
HK40096809A (zh) 拮抗性抗肿瘤坏死因子受体超家族抗体
HK40104763A (zh) 拮抗性抗肿瘤坏死因子受体超家族抗体
HK40050964A (en) Antagonistic anti-tumor necrosis factor receptor superfamily polypeptides

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

B15 Application refused following examination

Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B15-EXM-PE0601 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

A16 Divisional, continuation or continuation in part application filed

Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A16-DIV-PA0104 (AS PROVIDED BY THE NATIONAL OFFICE)

PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A16-div-PA0104